Brought to you by 
Bayer proposes to buy radiopharmaceutical partner Algeta for $2.4bn; offer increased, finalized
26 Aug 2020
Executive Summary
Bayer AG proposed to buy its radiopharmaceutical partner, publicly traded Algeta ASA, for NOK336 ($55.11) per share, a 27% premium, valuing Algeta at $2.4bn.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Bayer proposes to buy radiopharmaceutical partner Algeta for $2.4bn; offer increased, finalized
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice